reports
Dime Announces Appointment of Meyer Eichler as Executive Vice Presiden...
Dime Announces Appointment of Meyer Eichler as Executive Vice President, Managing Executive Director Demonstrates Dime’s Commitment to the Orthodox Jewish Community HAUPPAUGE, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Dime today announced that Meyer Eichler has joined the Bank as Executive Vice President, Managing Executive Director. In this role, Mr. Eichler will be responsible for expanding Dime’s presence within the Orthodox Jewish community across Manhattan, Brooklyn, Lakewood, New Jersey, and other key markets with a significant Orthodox Jewish population. Mr. Eichler most recently...
Dime Announces Significant Hires to Advance Growth Plan
Dime Announces Significant Hires to Advance Growth Plan HAUPPAUGE, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Building upon its reputation as the "bank-of-choice" for talented commercial bankers and the primary beneficiary of disruption in the Metro New York Market, Dime announced the following hires: Meyer Eichler, previously Executive Vice President and Head of Community Markets at Flagstar, has joined as Executive Vice President, Managing Executive Director, and he will lead a team of bankers. Prior to Flagstar, Mr. Eichler was with predecessor bank Signature (for approximately 13 years...
Outlook Therapeutics Announces Formal Dispute Resolution Request for O...
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS...
Dime To Transfer To New York Stock Exchange
Dime To Transfer To New York Stock Exchange HAUPPAUGE, N.Y., April 02, 2026 (GLOBE NEWSWIRE) -- Dime announces the transfer of all of its publicly traded securities to the New York Stock Exchange (“NYSE”). The first day of trading on NYSE will be April 7th, 2026. The Common Stock will continue to trade under “DCOM”, the Preferred Stock will trade under “DCOM PR”, and the fixed-to-floating rate subordinated notes due 2034 will trade under the “DCBG” ticker symbols respectively. "I am proud to announce Dime’s transfer to the New York Stock Exchange. The NYSE is an iconic exchange and home ...
LeonaBio Reports Full Year 2025 Financial Results and Provides Busines...
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complet...
Dime Declares Quarterly Cash Dividend for Common Stock
Dime Declares Quarterly Cash Dividend for Common Stock HAUPPAUGE, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Dime announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on April 24, 2026 to common stockholders of record as of April 17, 2026. The Company continues its trend of uninterrupted dividends. ABOUT DIME Dime is a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island (1). Investor Relations Contact:Avinash ReddySenior Executive Vice...
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Ea...
Dime To Sponsor LPGA Golfer Lexi Thompson
Dime To Sponsor LPGA Golfer Lexi Thompson HAUPPAUGE, N.Y., March 24, 2026 (GLOBE NEWSWIRE) -- Dime is proud to announce a new partnership with Lexi Thompson, one of the most recognizable and accomplished athletes in professional golf. Through this sponsorship, Dime will support Thompson on initiatives that promote community engagement and the advancement of women in sports. "I am incredibly proud to partner with DIME, an institution that defines stability and community commitment. Joining a team with a 162-year history of excellence is a true honor. I look forward to representing a bran...
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.2...
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics Announces Proposed Public Offering ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to th...
Dime Continues to Execute Growth Plan With Hire of Michael Ragusa
Dime Continues to Execute Growth Plan With Hire of Michael Ragusa Committed to De Novo Growth Strategy In Lakewood HAUPPAUGE, N.Y., March 16, 2026 (GLOBE NEWSWIRE) -- Dime today announced the hiring of Michael J. Ragusa Jr., as part of its Lakewood, NJ expansion efforts. Mr. Ragusa, who will be appointed First Vice President, will focus on delivering customized banking solutions to businesses and high net worth individuals in the rapidly growing Lakewood community, further strengthening Dime’s expanding Private and Commercial Banking platform in the area. The addition of Mr. Ragusa com...
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note ...
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the “Existing Note”) and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC (the “New Note”). Under the amendment to the Existing Note, the maturity date of the Ex...
Outlook Therapeutics Provides Update Following Type A Meeting with FDA...
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was c...
Dime Announces Elevation of Charlie Terrasi to Head of Investor CRE an...
Dime Announces Elevation of Charlie Terrasi to Head of Investor CRE and Multifamily HAUPPAUGE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Dime announced today the elevation of Charlie Terrasi to Head of Investor Commercial Real Estate and Multifamily. Mr. Terrasi will manage and oversee growth in the Company’s Investor CRE portfolio, in addition to his current oversight of the multifamily portfolio. Stuart H. Lubow, CEO and President, stated, "As a result of Charlie's successful leadership and management of the Bank’s multifamily portfolio, he will take on the additional responsibility of ...
Dime Announces Elevation of Jeffrey Barber to Head of Middle Market C&...
Dime Announces Elevation of Jeffrey Barber to Head of Middle Market C&I Lending, Long Island HAUPPAUGE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Dime announced today the elevation of Jeffrey Barber to Head of Middle Market Commercial & Industrial Lending, Long Island. This reflects Dime's continued commitment to expanding and strengthening its middle market platform. Mr. Barber will lead Dime's middle market C&I strategy for Dime's Long Island markets. In addition to overseeing relationship management and loan growth initiatives for privately held middle market businesses, he will manage ...
CORRECTION -- Dime Community Bank to Rebrand as Dime Commercial Bank
CORRECTION -- Dime Community Bank to Rebrand as Dime Commercial Bank Company to Transfer Listing of Its Securities to New York Stock Exchange HAUPPAUGE, N.Y., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that, subject to shareholder approval, it will change its name to “Dime Commercial Bancshares, Inc.”. The Bank’s name will change to “Dime Commercial Bank”. These changes will be effective soon after the Annual Shareholder Meeting (May 28, 2026), where there will be a v...
Dime Community Bank to Rebrand as Dime Commercial Bank Company to Tran...
Dime Community Bank to Rebrand as Dime Commercial Bank Company to Transfer Listing of Its Securities to New York Stock Exchange HAUPPAUGE, N.Y., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that, subject to shareholder approval, it will change its name to “Dime Commercial Bancshares, Inc.”. The Bank’s name will change to “Dime Commercial Bank”. These changes will be effective soon after the Annual Shareholder Meeting (May 28, 2026), where there will be a vote to approve t...
Outlook Therapeutics Expands European Footprint with Exclusive Commerc...
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasda...
Dime Awards Grant to LIEOC for Community Services
Dime Awards Grant to LIEOC for Community Services HAUPPAUGE, N.Y., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced that Dime has awarded a grant to Long Island Economic Opportunity Collaborative ("LIEOC") in support of academic and vocational training opportunities designed to foster personal growth, career advancement, and social mobility services in Nassau and Suffolk counties. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial ...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.